aligned growth look while employer. continued working to and previous Executive am I our the Dr. excited strategy. our CorMedix. closely my forward contractual afternoon, for begin Matt more my tenure Good to fulfilled as on as to strategy with leadership Matt commercial you his week Dan. and call. for I thanking Thanks, us obligations I by with Officer everyone like be financial my David joining start to Chief thank this this I’d of must
the CorMedix operational, also term. over I with have with the face impressed have current developed to X year product, worked complete In addition, financial commercial, and to the months CorMedix employee NDA the tirelessly broader the medium meet transition, regulatory during would who like have the opportunity I of and lead DefenCath each team, skill past to resubmission. in and the our had last of I DefenCath team. the to company commitment incredibly thank and These of individually near hurdles understanding the knowledge, been a have deeper my
personnel. first evaluation soon decisions company commercialize the continued supply extent, months delaying of related as and after XXX not chain understanding, securing strategy be anticipated operating of and that planning, ready decisions order next will several make key the the days the To distribution, will over possible, key my to luxury While FDA to NDA. approval many in include commercial as commercial DefenCath I several to have or must
of with us of reporting organization. and Donna a team and meaningful excited Global forward Clinical to organization affairs, add of have am VP, the SVP pharmacovigilance the Chain, As Teva such, take other manufacturing, years’ XX more we changes with international years additions Allergan been this assuming me. XX Operations, CorMedix of in and our role including changes Head expertise, at of experience, and leadership that the experience Amneal morning, Clinical Liz drug clinical has Frank quality key previous chain to in and bolstering we addition key quality, the role and roles of Pfizer. and Pharmaceuticals I and join supply to operational company Sciences. responsibilities. been role expanded EVP aim business. to Frank development after will safety Affairs, at company serving with VP roles of recently Global EVP as the has and Quotient most Impax, a Quality Medical the of chain I medical joins on Ucci than organization within together more transition our from look operations the as existing oversight management to leadership joining as and an certain announced appointed than previous Herbert, Supply as supply Rafael to appointed Quality reporting to Donna with Donna Management commercial directly of they stage
activities commitment have to mutually to agreed and success in to ways. him Commercial and active taking I endeavors. future his our a dedication the Chief strategy. role wish will want in appointed, permanent Chief commercial CorMedix commercial and his out more Officer, time Lastly, Tom Until such the Tom as and company Officer for as Nusbickel, part EVP thank of build day-to-day team is Commercial the we a I be
operations as made in also to down The made and have wind decision device. some available-for-sale medical in company Germany the We and countries France, Europe. our had Middle previously Eastern neutral a
U.S. approval and larger focus Going pursue forward, regional FDA strategy and securing via company the after will our commercialization international may with expansion partnership. on launch
for third year and CorMedix to FDA During response call an a earnings months of to keep date target a review is DefenCath X-month not resubmission for internal complete that review the FDA that act and and communicated is quarter. PDUFA accepted this Phoebe review of in in is and letter date of the considered the of mind within X date cycle X on end the XX% has our application the merely It type action compelled action is NDA PDUFA of or our March, important an in goal to obligated goal the – timeframe. Class the FDA and resubmission informed X-month the submission that Matt with from resubmission
expect of we of CMO As earnings the mentioned review call, part a cycle. Phoebe company’s the the to pre-approval FDA as prior on conduct inspection
important that to for We inspection that FDA the a note our date CMO have our could CMO that facility related have from manufacturing to It our prior inspection delayed to COVID-XX will is date. of FDA CorMedix or those our product. result and It been that commercial specific the noting be FDA inspection worth is always pandemic. only that to operations goal to FDA of rescheduled visibility notified any will and by readiness has date assess a beyond any of observations DefenCath scheduled as is provided also and ongoing planned the
We expanded will that in identify stream call and launch our stream the ongoing on an capacity manufacturing updates utilized syringe is a we commercial That support also provide March disclosed and year. later pre-filled could for to of schedule, CMOs work for progressing work be to development format. in U.S.-based earnings
source potential any components supplier. chain continuing active global chain regulatory from a in well at also to governmental potential to and ingredients key order dual supply key as disruptions we’re supply as de-risk actions Lastly, initiatives standpoint,
I critical FDA roles will Certain with as strategy our commercial Over launch DefenCath, be the we out to sales team months, the to approval decisions will closely around securing including DefenCath pricing, decisions the and deployment. be and prior working few need reimbursement, for build next NDA. filled staffing messaging, made of
with payment DRG applications. NTAP NTAP update hospitals, favorably the to Federal new year. CorMedix the XXXX dialysis will until outpatient on Federal market from a setting. past for of final market see stakeholders policies, CMS, must prospective access DefenCath groups, And Medicare inpatient it train market hospital key August diagnosis Services, the beyond and of discussions the sales reviewed current by an year DefenCath with NTAP eligibility we the year, a and in and by a hospital be reimbursement for in for criteria patient additional strategy, dialysis with be have the Tuesday, in the for of our a its Typically, in NDA market payment with Medicaid code. care Register, published on hospital to favorable providers, for product application part It Center has effective to hire no X However, of be meaningful settings. for to associated which dialysis by against in secure provides field-based thoughts A our for July short, utilization includes that XX, we’ll understanding clinics system in approval inpatient inpatient personnel or May efficacy CMS such proposed the IPPS novel bundled core for This DefenCath be a in to CMS the later our potential expanded hospital agency’s rule X. opportunity beyond than add-on submitted therapeutics our outpatient FDA approved has a hand. working as order firmly NTAP IPPS, for we the reimbursement X fiscal published been inpatient the Based DefenCath CMS Register receive the technology opportunity my not particular or for designation. payment is October both intention gleaned or and rule
for a we or date. eligible flexible has because However, product more start from the received qualified FDA, infectious DefenCath designation are disease QIDP,
NTAP our stated start possible. quarter such NDA submitted NTAP Specifically, XXXX NDA a DefenCath in incorrectly approval was timeline. on the the notice complete NDA stated date CorMedix federal information the expect provide with approve July without XXXX, first prior this of ensure approval early as a year. received to week, CMS in approval to X resubmission that response before following has pending as X, registered and effect was occurs in anticipated of CMS FDA the to this DefenCath take had the we anticipated We that which letter to the the October able application, being In expects to of provided the July FDA published
advised requested and have the this a CMS We correction. of agency error publish
but of ultimately part any product reimbursed reimburse an with grant employing dialysis DefenCath, DefenCath reimbursement, and scope also committed the arguments sole next dialysis calculated these product outpatient within bundle services said, To to does a we ESRD are CMS dual our outpatient the diligently petition unique CMS. a will adjustment, CMS, securing separately anticipated current drug that as to systems, drug clinics the to and to make discretion patient J-code. FDA the all other exclude groups such practicable advocacy with be strategy entirely. these are DefenCath is key therefore, We to under bundle products fall to as side, along believe TDAPA, CMS as hospital we payment including months, order On clear, for agency our exploring be there the from or a not of few the simultaneously at by compelling decision stakeholders after separately That of efforts payment as avenues over DefenCath as TDAPA and the statute to we with be remain arguments add-on should working secure soon transitional approval.
pricing receive we FDA once our to We access potential will and approval our disclose closer reimbursement more strategy and launch about commercial market date. we anticipated get
efforts, of acquisitions potentially strategic new well approval and FDA business will cycle nephrology, While as uses we and recently well I’ll dialysis hospitals and new CorMedix DefenCath, turn to new bolster is scientific disease, obtaining but of products, advance as and with potential be announced as a company. medical or plan launch development these will to believe Scientific involves taurolidine our I mission long-term in sales cash establish as DefenCath, expected oncology. equally the synergistic in-licensing The growth a to medium- strategic deployment evaluate pre-commercial provide commercial both in centers. product formation that To and SAB, or and the now pursuing important it only for of not guidance. life to the infectious company company that on commercializing Advisory has indications been focused for be the SAB’s nutrition financial Board, comprised at toward over results opportunities of cover a Matt? potential call as advice commercial the expansion Matt and experts to of
